$ATMV
AlphaVest Acquisition Corp.

2024 Q1 Form 10-Q Financial Statement

#000149315224020758 Filed on May 20, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $236.9K $158.2K
YoY Change 49.78%
Operating Profit -$236.9K -$158.2K
YoY Change 49.78% 4119.45%
Interest Expense $586.2K $803.1K
YoY Change -27.01%
% of Operating Profit
Other Income/Expense, Net $30.00K $803.1K
YoY Change -96.26%
Pretax Income $349.2K $644.9K
YoY Change -45.85%
Income Tax
% Of Pretax Income
Net Earnings $349.2K $644.9K
YoY Change -45.85% -17301.87%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.05 $0.07
COMMON SHARES
Basic Shares Outstanding 9.181M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.79K $311.0K
YoY Change -95.57%
Cash & Equivalents $13.79K $311.0K
Short-Term Investments
Other Short-Term Assets $78.59K $54.30K
YoY Change 44.73%
Inventory
Prepaid Expenses $78.59K $54.30K
Receivables
Other Receivables
Total Short-Term Assets $92.38K $365.3K
YoY Change -74.71%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $51.47M $71.22M
YoY Change -27.74%
Other Assets $55.00K $32.38K
YoY Change 69.86%
Total Long-Term Assets $51.52M $71.25M
YoY Change -27.69%
TOTAL ASSETS
Total Short-Term Assets $92.38K $365.3K
Total Long-Term Assets $51.52M $71.25M
Total Assets $51.61M $71.62M
YoY Change -27.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $413.4K $29.58K
YoY Change 1297.53%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $285.9K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $709.1K $39.41K
YoY Change 1699.26%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $709.1K $39.41K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $709.1K $39.41K
YoY Change 1699.35%
SHAREHOLDERS EQUITY
Retained Earnings -$617.0K $358.0K
YoY Change -272.34%
Common Stock $228.00 $228.00
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$616.7K $358.2K
YoY Change
Total Liabilities & Shareholders Equity $51.61M $71.62M
YoY Change -27.93%

Cashflow Statement

Concept 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income $349.2K $644.9K
YoY Change -45.85% -17301.87%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$14.77K -$348.1K
YoY Change -95.76%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$55.00K
YoY Change
Cash From Investing Activities -$55.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $55.00K
YoY Change
NET CHANGE
Cash From Operating Activities -$14.77K -$348.1K
Cash From Investing Activities -$55.00K
Cash From Financing Activities $55.00K
Net Change In Cash -$14.77K -$348.1K
YoY Change -95.76%
FREE CASH FLOW
Cash From Operating Activities -$14.77K -$348.1K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
usd
CY2023Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
usd
CY2023Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
usd
CY2023Q1 us-gaap Increase Decrease In Notes Payable Related Parties Current
IncreaseDecreaseInNotesPayableRelatedPartiesCurrent
usd
CY2023Q1 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q1 ATMV Accrued Expenses Converted To Promissory Note
AccruedExpensesConvertedToPromissoryNote
usd
CY2024Q1 us-gaap Cash
Cash
13791 usd
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
78588 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
92379 usd
CY2024Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
51466768 usd
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
50880604 usd
CY2024Q1 us-gaap Assets
Assets
51614147 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
413385 usd
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
285902 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
165000 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
709124 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
387955 usd
CY2024Q1 us-gaap Liabilities
Liabilities
709124 usd
CY2023Q4 us-gaap Liabilities
Liabilities
387955 usd
CY2024Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
4725829 shares
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
4725829 shares
CY2024Q1 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.90
CY2023Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.77
CY2024Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
51521768 usd
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
50880604 usd
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2280500 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2280500 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2280500 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2280500 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
228 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
228 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-616973 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-325050 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-616745 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-324822 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
51614147 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50943737 usd
CY2024Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
236926 usd
CY2023Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
158187 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-236926 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-158187 usd
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
678480 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
802992 usd
CY2024Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
-92316 usd
CY2024Q1 us-gaap Interest Income Other
InterestIncomeOther
3 usd
CY2023Q1 us-gaap Interest Income Other
InterestIncomeOther
93 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
586167 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
803085 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
349241 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
644898 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
554543 usd
CY2023Q1 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
-841219 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
644898 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
358222 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-324822 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-324822 usd
CY2024Q1 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
-586164 usd
CY2024Q1 ATMV Stock Redeemed Or Called During Period Value One
StockRedeemedOrCalledDuringPeriodValueOne
-55000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
349241 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-616745 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-616745 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
644898 usd
CY2024Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
678480 usd
CY2023Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
802992 usd
CY2024Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
-92316 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-37522 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-28468 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
170097 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-218459 usd
CY2024Q1 us-gaap Increase Decrease In Notes Payable Related Parties Current
IncreaseDecreaseInNotesPayableRelatedPartiesCurrent
14535 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14769 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-348085 usd
CY2024Q1 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
55000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-55000 usd
CY2024Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
55000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14769 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-348085 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28560 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
659035 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13791 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
310950 usd
CY2024Q1 us-gaap Stock Issued1
StockIssued1
586164 usd
CY2023Q1 us-gaap Stock Issued1
StockIssued1
841220 usd
CY2024Q1 ATMV Accrued Expenses Converted To Promissory Note
AccruedExpensesConvertedToPromissoryNote
51367 usd
CY2022Q4 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
61200000 usd
CY2022Q4 ATMV Cash Deposited In Trust Account Per Unit
CashDepositedInTrustAccountPerUnit
10.20
CY2024Q1 ATMV Percentage Of Public Shares That Would Not Be Redeemed If Business Combination Is Not Completed Within Initial Combination Period
PercentageOfPublicSharesThatWouldNotBeRedeemedIfBusinessCombinationIsNotCompletedWithinInitialCombinationPeriod
1 pure
CY2024Q1 us-gaap Liquidation Basis Of Accounting Accrued Costs To Dispose Of Assets And Liabilities
LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
100000 usd
CY2023Q4 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
2174171 shares
CY2023Q4 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
23282936 usd
CY2023Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10.71
CY2024Q2 us-gaap Escrow Deposit
EscrowDeposit
275000 usd
CY2024Q1 us-gaap Cash
Cash
13791 usd
CY2024Q1 ATMV Working Capital
WorkingCapital
616745 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_846_eus-gaap--UseOfEstimates_zzqUFX1BxTq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_ztfx0VS7wQEg">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the financial statement in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13791 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28560 usd
CY2024Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
51466768 usd
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
50880604 usd
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
678480 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
802992 usd
CY2024Q1 ATMV Offering Costs
OfferingCosts
55000 usd
CY2024Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2024Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_z8qVRo4TEMJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zBt9ZHnZYCb1">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20240331_z5ZIYyRVerY8" title="Federal Depository Insurance Coverage">250,000</span>. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
50880604 usd
CY2024Q1 ATMV Stock Issued During Period Value For Common Stock Subject To Redemption Amount Investment Held In Trust Account
StockIssuedDuringPeriodValueForCommonStockSubjectToRedemptionAmountInvestmentHeldInTrustAccount
586164 usd
CY2024Q1 ATMV Stock Issued During Period Value For Common Stock Subject To Redemption Amount Extension Deposit
StockIssuedDuringPeriodValueForCommonStockSubjectToRedemptionAmountExtensionDeposit
55000 usd
CY2024Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
51521768 usd
CY2024Q1 us-gaap Professional Fees
ProfessionalFees
30000 usd
CY2024Q1 us-gaap Other Expenses
OtherExpenses
30000 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
30000 usd
CY2022Q2 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
150000 usd
CY2024Q1 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
0 usd
CY2023Q4 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
0 usd
CY2024Q1 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
400000 usd
CY2024Q1 us-gaap Other Comprehensive Income Defined Benefit Plan Net Prior Service Costs Credit Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax
537 usd
CY2023Q1 us-gaap Other Comprehensive Income Defined Benefit Plan Net Prior Service Costs Credit Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax
784 usd
CY2024Q1 us-gaap Other Comprehensive Income Defined Benefit Plan Net Prior Service Costs Credit Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax
157 usd
CY2023Q1 us-gaap Other Comprehensive Income Defined Benefit Plan Net Prior Service Costs Credit Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax
79 usd
CY2022Q4 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
1725000 usd
CY2024Q1 ATMV Percentage Of Cash Fee On Consideration Payable In Initial Business Combination
PercentageOfCashFeeOnConsiderationPayableInInitialBusinessCombination
0.010 pure
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2280500 shares
CY2024Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
4725829 shares
CY2024Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
92316 usd

Files In Submission

Name View Source Status
atmv-20240331_pre.xml Edgar Link unprocessable
0001493152-24-020758-index-headers.html Edgar Link pending
0001493152-24-020758-index.html Edgar Link pending
0001493152-24-020758.txt Edgar Link pending
0001493152-24-020758-xbrl.zip Edgar Link pending
atmv-20240331.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
atmv-20240331_cal.xml Edgar Link unprocessable
atmv-20240331_def.xml Edgar Link unprocessable
atmv-20240331_lab.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable